Orexo AB (OTCPK:ORXOF)
$ 1.08 0 (0%) Market Cap: 54.89 Mil Enterprise Value: 98.19 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 57/100

Q3 2023 Orexo AB Earnings Call Transcript

Nov 02, 2023 / 01:00PM GMT
Release Date Price: $1.55
Operator

This call is being recorded.

Welcome to Orexo Q3 report 2023.

(Operator Instructions) Now I will hand the conference over to CEO, Nikolaj Sørensen and CFO, Fredrik Järrsten. Please go ahead.

Nikolaj SÃ;rensen
Orexo AB - President and CEO

¸ -

Welcome to this third quarter call for Orexo. As most of you probably have seen, it's a mixed bag of news in the third quarter. We have had some good developments in several areas, but we also have some areas which have not really met our expectations for the quarter and where we've been a little disappointed.

The big thing for the quarter is, of course, the filing of OX124 in the US. It's rare in Sweden that pharmaceutical companies file for product for approval. And we're quite proud that we once again have filled. OX124 even though admittedly this time was a refiling, but relatively shortly after we received the notification from FDA that they didn't accept our first file.

As was said in the introduction, I'm joined by Fredrik Järrsten, who will go through the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot